Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito(Kanagawa Cancer Center), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Naoki Furuya(St. Marianna University School of Medicine), Kana Watanabe(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Shunichiro Iwasawa(Chiba University), Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Ou Yamaguchi(Saitama Medical University), Morihito Okada(Hiroshima University Hospital), Kozo Yoshimori(Fukujuji Hospital), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Akihiko Gemma(Nippon Medical School), Koichi Azuma(Kurume University), Futoshi Kurimoto(Saitama Cancer Center), Yukari Tsubata(Shimane University), Yuka Fujita(Asahikawa Medical University), Hiromi Nagashima(Iwate Medical University), Gyo Asai(Aichi Cancer Center), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Masaki Miyazaki(Suita Municipal Hospital), Koichi Hagiwara(Jichi Medical University), Toshihiro Nukiwa(Tohoku University), Satoshi Morita(Kyoto University), Kunihiko Kobayashi(Saitama Medical University), Makoto Maemondo(Iwate Medical University)
The Lancet Oncology
April 8, 2019
10.1016/s1470-2045(19)30035-x
Cited by 634Open Access
Full Text

Abstract

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al.|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais et al.|The Lancet Oncology|2012|5.5k
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Joan H. Schiller, David Harrington, Chandra P. Belani et al.|New England Journal of Medicine|2002|5k
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe et al.|The Lancet Oncology|2009|4.1k
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al.|Science Translational Medicine|2011|3.6k